throbber
CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`
`APPLICATION NUMBER:
`022501Orig1s000
`
`MICROBIOLOGY REVIEW(S)
`
`
`
`
`
`
`
`

`

`
`
`
`
`Product Quality Microbiology Review
`
`December 22, 2009
`
`
`
`
`
`
`22-501 Amendment
`
`
`
`
`NDA:
`
`Drug Product Name
`Proprietary:
`
`
`
`
`Non-proprietary: Norethindrone acetate & Ethinyl estradiol tablets
`
`
` Ethyinyl estradiol tablets &
`
`
`
`Ferrous fumarate tablets
`
`2
`
`
`
`
`Review Number:
`
`
`Dates of Submission(s) Covered by this Review
`Assigned to
`Submit
`Received
`Review Request
`Reviewer
`December 17, 2009 December 17, 2009 December 18, 2009 December 18, 2009
`
`
`
`Submission History (for amendments only)
`Submit Date(s)
`Microbiology Review #
`March 26, 2009
`1
`
`Review Date(s)
`November 20, 2009
`
`Warner Chilcott Company, Inc.
`100 Enterprise Drive, Roackaway, NJ 07866
`Alvin Howard, Sr. Vice President, RA
`973-442-3233
`
`Vinayak B. Pawar, Ph.D.
`
`The amended original NDA is recommended for
`approval from Product Quality Microbiology
`standpoint.
`
`
`
`Applicant/Sponsor
`Name:
`
`
`Address:
`
`Representative:
`Telephone:
`
`
`
`Name of Reviewer:
`
`Conclusion:
`
`
`
`
`
`
`
`(b) (4)
`
`

`

`NDA 22-501
`
`
`
`Product Quality Microbiology Data Sheet
`
`A.
`1.
`TYPE OF SUBMISSION: Amended original NDA
`
`2.
`
`Microbiology Review # 2
`
`
`SUBMISSION PROVIDES FOR: An agreement to add Microbial
`Limits test criteria to the drug product specification.
`
`
`
`MANUFACTURING SITE: Warner Chilcott Co. Inc., Fajardo, PR
`00738
`
`.
`
`3.
`
`
`4.
`
`B.
`
`C.
`
`DOSAGE FORM, ROUTE OF ADMINISTRATION AND
`STRENGTH/POTENCY: Oral Tablets in 1mg NA, 10 mcg EE and 10
`mcg EE.
`
`METHOD(S) OF STERILIZATION: Non-sterile product.
`
`PHARMACOLOGICAL CATEGORY: Prevention of pregnancy.
`
`
`5.
`
`6.
`
`SUPPORTING/RELATED DOCUMENTS: None.
`
`REMARKS: The consult requests review of NDA 22-501 an oral drug product
` (Norethindrone acetate & Ethinyl estradiol tablets, Ethyinyl
`estradiol tablets & Ferrous fumarate tablets) for product quality microbiology
`review. The applicant proposed no microbial testing for the oral tablets. This
`resulted in a deficiency which was conveyed to Warner Chilcott and the sponsor
`was given the opportunity to discuss this deficiency in teleconference with the
`reviewer. In the teleconference held on December 14, 2009 Warner Chilcott
`agreed to amend the application to include the Microbial Limits test in their
`product specification.
`
`
`
`
`
`
`filename: C:\my documents\review\NDA\NO22501R2
`
`
`
`
`
`
`
`Page 2 of 6
`
`
`
`(b) (4)
`
`

`

`NDA 22-501
`
`Executive Summary
`
`
`
`
`
`Microbiology Review # 2
`
`
`Recommendations
`
`A.
`
`Recommendation on Approvability – The amended original
`NDA is recommended for approval.
`
`
`B.
`
`Recommendations on Phase 4 Commitments and/or
`Agreements, if Approvable – N/A
`
`
`Summary of Microbiology Assessments
`
`I.
`
`II.
`
`
`A. Brief Description of the Manufacturing Processes that relate to
`Product Quality Microbiology – WC3016 1/l0 tablets are made
`
`
`
`
`
`
`Brief Description of Microbiology Deficiencies – None
`
`Assessment of Risk Due to Microbiology Deficiencies – N/A.
`
`
`B.
`
`C.
`
`III. Administrative
`
`
`A.
`
`
`
`B.
`
`
`C.
`
`Reviewer's Signature _____________________________
` Vinayak B. Pawar, Ph.D.
`
`
`
`Endorsement Block _____________________________
`
`
`
`Stephen E. Langille, Ph.D.
`
`CC Block
`N/A
`
`
`
`
`
`
`
`Page 3 of 6
`
`
`
`
`
`
`
`(b) (4)
`
`3 Page(s) has ben Withheld in Full as b4 (CCI/TS) immediately
`following this page
`
`

`

`Application
`Type/Number
`--------------------
`NDA-22501
`
`Submission
`Type/Number
`--------------------
`ORIG-1
`
`Submitter Name
`
`Product Name
`
`--------------------
`WARNER
`CHILCOTT CO INC
`
`------------------------------------------
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`VINAYAK B PAWAR
`12/23/2009
`
`STEPHEN E LANGILLE
`12/23/2009
`
`(b) (4)
`
`

`

`Product Quality Microbiology Review
`
`November 20, 2009
`
`
`
`
`
`
`22-501
`
`
`
`
`
`
`NDA:
`
`Drug Product Name
`Proprietary:
`
`
`
`
`Non-proprietary: Norethindrone acetate & Ethinyl estradiol tablets
`
`
` Ethyinyl estradiol tablets &
`
`
`
`Ferrous fumarate tablets
`
`
`
`
`Review Number:
`
`
`Dates of Submission(s) Covered by this Review
`Submit
`Received
`Review Request
`March 26, 2009 March 27, 2009
`September 16, 2009
`
`
`Submission History (for amendments only) – N/A
`
`
`Applicant/Sponsor
`Name:
`
`
`Address:
`
`Representative:
`Telephone:
`
`
`1
`
`Assigned to Reviewer
`September 17, 2009
`
`Warner Chilcott Company, Inc.
`100 Enterprise Drive, Roackaway, NJ 07866
`Alvin Howard, Sr. Vice President, RA
`973-442-3233
`
`Vinayak B. Pawar, Ph.D.
`
`The NDA is approvable upon resolution of the
`deficiency listed in the Product Quality
`Microbiology Assessment, Section 3.
`
`
`Name of Reviewer:
`
`Conclusion:
`
`
`
`
`
`(b) (4)
`
`

`

`NDA 22-501
`
`
`
`Product Quality Microbiology Data Sheet
`
`A.
`1.
`TYPE OF SUBMISSION:
`Original NDA
`
`2.
`
`Microbiology Review # 1
`
`
`SUBMISSION PROVIDES FOR: A new drug application.
`
`MANUFACTURING SITE: Warner Chilcott Co. Inc., Fajardo, PR
`00738
`
`3.
`
`
`4.
`
`B.
`
`C.
`
`DOSAGE FORM, ROUTE OF ADMINISTRATION AND
`STRENGTH/POTENCY: Oral Tablets in 1mg NA, 10 mcg EE and 10
`mcg EE.
`
`METHOD(S) OF STERILIZATION: Non-sterile product.
`
`PHARMACOLOGICAL CATEGORY: Prevention of pregnancy.
`
`
`5.
`
`6.
`
`SUPPORTING/RELATED DOCUMENTS: None.
`
`REMARKS: The consult requests review of NDA 22-501 an oral drug product
` (Norethindrone acetate & Ethinyl estradiol tablets, Ethyinyl
`estradiol tablets & Ferrous fumarate tablets) for product quality microbiology
`review. The applicant proposes no microbial testing for the oral tablets.
`
`
`
`
`
`
`filename: C:\my documents\review\NDA\NO22501R1
`
`
`
`
`
`
`
`Page 2 of 9
`
`
`
`(b) (4)
`
`

`

`NDA 22-501
`
`Executive Summary
`
`
`
`
`
`Microbiology Review # 1
`
`
`Recommendations
`
`A.
`
`Recommendation on Approvability – This submission is
`approvable pending resolution of the deficiency listed in Product
`Quality Microbiology Assessment Section 3 of this review.
`
`
`B.
`
`Recommendations on Phase 4 Commitments and/or
`Agreements, if Approvable – N/A
`
`
`Summary of Microbiology Assessments
`
`I.
`
`II.
`
`
`A. Brief Description of the Manufacturing Processes that relate to
`Product Quality Microbiology – WC3016 1/l0 tablets are made
`
`
`
`
`
`
`
`
`
`
`Brief Description of Microbiology Deficiencies – Microbial
`Limits test is not performed.
`
`Assessment of Risk Due to Microbiology Deficiencies – a
`medium risk due to inability to assess microbial contamination in
`the product.
`
`Reviewer's Signature _____________________________
` Vinayak B. Pawar, Ph.D.
`
`
`
`Endorsement Block _____________________________
`
`
`
`Stephen E. Langille, Ph.D.
`
`CC Block
`N/A
`
`
`B.
`
`
`C.
`
`A.
`
`
`
`B.
`
`
`C.
`
`
`III. Administrative
`
`
`
`
`
`
`
`
`Page 3 of 9
`
`
`
`6 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately
`following this page
`
`(b) (4)
`
`

`

`Application
`Type/Number
`--------------------
`NDA-22501
`
`Submission
`Type/Number
`--------------------
`ORIG-1
`
`Submitter Name
`
`Product Name
`
`--------------------
`WARNER
`CHILCOTT CO INC
`
`------------------------------------------
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`VINAYAK B PAWAR
`11/24/2009
`
`STEPHEN E LANGILLE
`11/25/2009
`
`(b) (4)
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket